Literature DB >> 12898516

Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway.

Elizabeth S Henson1, Erika M Gibson, Jacylyn Villanueva, Nicolle A Bristow, Neil Haney, Spencer B Gibson.   

Abstract

Epidermal growth factor (EGF) protects against death receptor induced apoptosis in epithelial cells. Herein, we demonstrate that EGF protection against tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced apoptosis is mediated by increased expression of the Bcl-2 family member myeloid cell leukemia 1 (Mcl-1). EGF increased the mRNA and protein levels of Mcl-1. Furthermore, expression of ErbB1 alone or in combination with ErbB2 in NIH3T3 cells up-regulates Mcl-1 following EGF treatment. In addition, up-regulation of Mcl-1 by EGF is mediated through AKT and NFkappaB activation since kinase inactive AKT and DeltaIkappaB effectively blocks this up-regulation. NFkappaB was also critical for the ability of EGF to prevent TRAIL induced apoptosis as a dominant negative IkappaB (DeltaIkappaB) blocked NFkappaB activation, and relieved EGF protection against TRAIL mediated mitochondrial cytochrome-c release and apoptosis. Finally, anti-sense oligonucleotides directed against Mcl-1 effectively reduced the protein levels of Mcl-1 and blocked EGF protection against TRAIL induced mitochondrial cytochrome-c release and apoptosis. Taken together, EGF signaling leads to increased Mcl-1 expression that is required for blockage of TRAIL induced apoptosis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898516     DOI: 10.1002/jcb.10597

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  25 in total

1.  Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.

Authors:  Shashirekha Shetty; Bonnie A Graham; Jennifer G Brown; Xiaojie Hu; Nicolette Vegh-Yarema; Gary Harding; James T Paul; Spencer B Gibson
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

2.  Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Authors:  Zhaoyang Li; Kenisha Younger; Ronald Gartenhaus; Ann Mary Joseph; Fang Hu; Maria R Baer; Patrick Brown; Eduardo Davila
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

3.  A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.

Authors:  Lina Y Dimberg; Christina G Towers; Kian Behbakht; Taylor J Hotz; Jihye Kim; Susan Fosmire; Christopher C Porter; Aik-Choon Tan; Andrew Thorburn; Heide L Ford
Journal:  Mol Cancer Res       Date:  2017-01-20       Impact factor: 5.852

4.  Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.

Authors:  Xingchao Zhu; Kaiguang Zhang; Qiaomin Wang; Si Chen; Yawen Gou; Yufang Cui; Qin Li
Journal:  Med Oncol       Date:  2015-03-22       Impact factor: 3.064

Review 5.  Caspase-8 as a regulator of tumor cell motility.

Authors:  R P Graf; N Keller; S Barbero; D Stupack
Journal:  Curr Mol Med       Date:  2014-02       Impact factor: 2.222

6.  Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.

Authors:  Bernhard Gillissen; Jana Wendt; Antje Richter; Anja Richter; Annika Müer; Tim Overkamp; Nina Gebhardt; Robert Preissner; Claus Belka; Bernd Dörken; Peter T Daniel
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

Review 7.  The TRAIL to targeted therapy of breast cancer.

Authors:  Monzur Rahman; Janet G Pumphrey; Stanley Lipkowitz
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

8.  ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.

Authors:  Jie Yang; Chunxu Yang; Shimin Zhang; Zijie Mei; Mingjun Shi; Shaoxing Sun; Liu Shi; Zhihao Wang; Yacheng Wang; Zhenzhen Li; Conghua Xie
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.

Authors:  Deborah A Flusberg; Peter K Sorger
Journal:  Phys Biol       Date:  2013-06-04       Impact factor: 2.583

10.  Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.

Authors:  Elizabeth S Henson; James B Johnston; Marek Los; Spencer B Gibson
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.